Efficacy and Safety of SHR3824 as Monotherapy in Subjects With Type 2 Diabetes
Status:
Unknown status
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to obtain information on efficacy and safety of SHR3824 over 24
weeks and 52 weeks in Chinese patients with Type 2 Diabetes. This will be done by comparing
the effect of SHR3824 to placebo when given in oral doses.